21 May 2026

GenIP Plc

("GenIP" or the "Company")

New Orders

GenIP Plc (AIM: GNIP), a technology consultancy providing AI-driven services to help research organisations and corporations commercialise their innovations, is pleased to announce the following new orders.

#1 Ranked Research University in Hong Kong

The Company has entered into a 12-month framework agreement with a leading Hong Kong research university, with an option to renew for a further 12 months. The agreement enables portfolio-level evaluations of up to 10 technologies per order, with orders placed by the university as required. The engagement is valued at approximately $20,000 per year, with potential for additional work beyond the initial scope.

Major UK Higher Education Institution

The Company has secured a first-time engagement with a well-established modern university in London, recognised for its strengths in applied research, engineering, and technology. The initial order covers 10 reports, with the likelihood of additional repeat orders to evaluate the institution's broad innovation portfolio.

South African Client: Invention Validator

A South African client has deployed the Company's recently launched Invention Validator product, representing one of the first engagements for this offering. The engagement is valued at approximately $14,500 for a single technology evaluation. The product is currently operating with a 60% margin floor, supporting strong unit economics as adoption scales.

Canadian and US Research Universities

The Company has secured its first Canadian client, one of Canada's leading research universities, with over 65,000 students and a strong international reputation in AI, engineering, health sciences, and technology research. The Company has also secured an engagement with one of North America's leading public research universities, internationally recognised for its programmes in engineering, AI, computer science, and technology innovation. Comparable institutions place orders monthly, and we are confident we'll maintain a similar relationship with our new clients.

The Company will announce their FY2025 results within the next two weeks and will include an outlook at that time.

Melissa Cruz, CEO of GenIP, commented:

"Securing a framework agreement with the #1 ranked university for patent influence in China is a major validation of our new AI-driven products.

More broadly, we are delighted with the response to our expanding range of products and believe GenIP is perfectly positioned for another year of top-line growth in 2026 as the number of long-term repeat customers grows."

For further information regarding GenIP, please visit www.genip.ai, or contact:

Beaumont Cornish Limited ("Beaumont Cornish") is the Company's Nominated Adviser and is authorised and regulated by the FCA. Beaumont Cornish's responsibilities as the Company's Nominated Adviser, including a responsibility to advise and guide the Company on its responsibilities under the AIM Rules for Companies and AIM Rules for Nominated Advisers, are owed solely to the London Stock Exchange. Beaumont Cornish is not acting for and will not be responsible to any other persons for providing protections afforded to customers of Beaumont Cornish nor for advising them in relation to the proposed arrangements described in this announcement or any matter referred to in it.

Notes to Editors

About GenIP

GenIP is a next-generation business      at the intersection of generative AI and innovation strategy. We empower corporates, venture funds, and research institutions to evaluate, commercialise, and scale breakthrough technologies. By combining proprietary GenAI algorithms with expert human analysis, GenIP delivers decision-grade insights and talent solutions that accelerate innovation outcomes.

Service Offerings

GenIP operates through two synergistic service lines:

Together, these services form a unified GenAI-enabled platform for innovation triage and execution.

Vision & Strategy

GenIP aims to become the global leader in generative AI analytics for innovation commercialisation. Our strategy is anchored in three growth pillars:

●    Organic Expansion
Scale Invention Evaluator and Recruitment Services through targeted outreach to corporates, VCs, and research institutions, supported by strategic marketing and digital engagement.

●    Service Deepening
Enhance functionality and margin by expanding GenAI capabilities within both service lines-unlocking new use cases and customer segments.

●    Strategic Acquisitions
Pursue bolt-on acquisitions of complementary GenAI services with validated market traction to broaden our offering and accelerate growth.

Forward looking statements

Certain statements contained in this announcement constitute forward-looking statements. When used in this announcement, the words "may", "would", "could", "will", "intend", "plan", "anticipate", "believe", "seek", "propose", "estimate", "expect", and similar expressions, as they relate to the Company, are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding intentions, beliefs or current expectations concerning, among other things, the Company's results of operations, financial position, liquidity, prospects, growth, strategies and expectations of the industry in which the Company operates.

Such statements reflect the Company's current views with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the Company's actual results, performance or achievements to materially differ from those described in this announcement Should one or more of these risks or uncertainties materialise, or should assumptions underlying forward-looking statements prove incorrect, actual results may differ materially from those described in this announcement as "intended", "planned", "anticipated", "believed", "proposed", "estimated" or "expected".

For the avoidance of doubt, the contents of the Company's website and any hyperlinks accessible from the Company's website are not incorporated by reference into, and do not form part of, this announcement and investors should not rely on them.

-ENDS-